- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03013959
Observation on the Herpes Simplex Keratitis (OHSV)
January 5, 2017 updated by: Yang Jiang, Peking Union Medical College
Observation on Effect of Anti--inflammatory and Inhibition of Recurrence on the Herpes Simplex Keratitis After Topical NSAIDs Administration
As is reported, NSAIDs(pranoprofen ,bromfenac) eye drops can suppress herpes simplex virus(HSV-1) reactivation and reduce inflammatory reaction in vitro and in vivo.
In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
To explore more effective clinical treatment of viral keratitis patients to control the inflammatory damage, save the visual function and reduce the recurrence of the virus ,we observe the effect of anti-inflammatory and inhibition of recurrence on the herpes simplex virus after topical NSAIDs administration.
Study Overview
Detailed Description
Viral keratitis has now become the highest incidence and the most severe-caused blindness corneal disease in the worldwide, as is superior to bacterial keratitis and fungal keratitis.
At present, clinical treatments mainly depend on local and systematic use of antiviral drugs for viral keratitis, which can inhibit replication of viruses in corneal tissues and directly damage viral action.
However, basal studies for viral keratitis have suggested that pathological immune injury produced by the body also play an important role in the formation of corneal ulcer, the damage of visual function in patients, during the necrotic stromal inflammation phase, endotheliitis phase and even serious combination of iridocyclitis phase of viral keratitis.
There is, however, a larger controversy in the hormone therapy for this disease clearly caused by pathological immune injury in medical world.
Patients with infectious keratitis caused by viral infection, who receive hormone treatment, may cause viral replication enhanced and out of control, and hormone itself could also cause spontaneous corneal tissues fusion; hence, treatments combined with hormone have a certain risks.
In clinical treatments, permanent corneal opacity caused by corneal inflammation responses will cause patients permanent visual acuity loss, after patients' corneal lesions were controlled with simple use of antiviral drugs.
Another important reason is the high incidence of blindness caused by viral keratitis: herpesvirus, such as herpes simplex virus and herpes zoster virus, will involve trigeminal ganglia and hide after primary infection, and will repeatedly recur under the stimulation of excessive drinking, menstruation, taking a cold and operation etc.. Viral keratitis often does not cause patients severe visual impairment at initial onset.
But, viruses in patients with herpes simplex virus keratitis show extremely high recurrence rates.
As suggested in epidemiologic studies in the Euro-American countries, its recurrence rate could be up to 30% in the first year, and 46% in the second years.
In most cases, transparent corneal tissues develop nephelium and even macular nebula opacities after repeated recurring, and patients eventually lose visual acuity, becoming people with blindness and disabilities.
Nonsteroidal antiinflammatory drugs, such as pranoprofen and bromfenac sodium, show significant inhibition of virus recurrence and relief of corneal inflammation responses in experiments in vitro and animal experiments, which indicated in previous studies.
In clinical, local application of nonsteroidal antiinflammatory drugs does not result in spontaneous corneal tissue fusion, drug-induced glaucoma, drug-induced cataract and other risks.
In order to seek more effective clinical treatments for viral keratitis patients in terms of controlling inflammation injury, preserving visual functions and reducing virus recurrence, this study observed that pranoprofen, a nonsteroidal antiinflammatory drug, inhibits pathological immune injury of viral keratitis and prevents this disease recurring, according to the basal research background of viral keratitis.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Jiang, md
- Phone Number: +8613521676533
- Email: jiangyangpumch@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yang Jiang, md
- Phone Number: +8613521676533
- Email: jiangyangpumch@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
- Eyes with typical stromal infiltration, typical herpes simplex virus keratitis patients
- Eyes with a history of recurrent erythema, pain, recurrent disease
Description
Inclusion Criteria:
- Eyes with typical stromal infiltration, typical herpes simplex virus keratitis patients
- Eyes with a history of recurrent erythema, pain, recurrent disease
Exclusion Criteria:
- Patients with immune dysfunction or receiving immunosuppressive therapy
- Patients with cardiac and pulmonary insufficiency
- Patients with liver function, renal insufficiency
- Patients with allergic reactions to related drugs
- Patients with history of corneal surgery
- Pregnant women and breast-feeding women
- Patients with diabetes
- Patients with malignant tumor history
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Resting control group
The rest group is to study the effect of the inhibition of recurrence .
Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
|
|
Resting test group
The rest group is to study the effect of the inhibition of recurrence .
Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
|
it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus(HSV-1) reactivation and reduce inflammatory reaction in vitro and in vivo.
In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
Other Names:
|
Active control group
The active control group is to study the effect of anti--inflammatory.
Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
|
|
Active test group
The active test group is to study the effect of anti--inflammatory.
Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
|
it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus(HSV-1) reactivation and reduce inflammatory reaction in vitro and in vivo.
In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
inhibition of recurrence on the herpes simplex virus
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ying Li, md, Peking Union Medical College
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (Anticipated)
March 1, 2018
Study Completion (Anticipated)
September 1, 2018
Study Registration Dates
First Submitted
January 5, 2017
First Submitted That Met QC Criteria
January 5, 2017
First Posted (Estimate)
January 9, 2017
Study Record Updates
Last Update Posted (Estimate)
January 9, 2017
Last Update Submitted That Met QC Criteria
January 5, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Eye Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Corneal Diseases
- Herpesviridae Infections
- Eye Infections
- Eye Infections, Viral
- Keratitis
- Herpes Simplex
- Keratitis, Herpetic
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Gout Suppressants
- Pyranoprofen
Other Study ID Numbers
- PekingUMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratitis, Herpetic
-
Farwaniya HospitalRecruitingOutcomes of Cyclosporine Eye Drops in Herpetic KeratitisKuwait
-
Icare Finland OyUnknownCorneal Dystrophy | Corneal Degeneration | Corneal Sensation Reduced | Corneal Transplant Failure | Herpetic Keratitis
-
Oregon Health and Science UniversityTissue Tech Inc.WithdrawnHerpes Simplex Dendritic KeratitisUnited States
-
CHU de Quebec-Universite LavalTerminatedHerpes Simplex KeratitisCanada
-
Chunxiao WangUnknownHerpes Simplex KeratitisChina
-
Beyoglu Eye Research and Education HospitalCompletedEndothelial Dysfunction | Fuchs' Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Herpetic Keratitis | Descemet's Membrane; Defect | Angle's ClassificationTurkey
-
University of UlsterBedford Hospital NHS Trust; Midlands Eye Clinic; Royal Victoria Hospital, BelfastCompletedHerpes Simplex KeratitisUnited Kingdom
-
National Eye Institute (NEI)CompletedHerpes Simplex | Keratitis, Herpetic | Ocular Herpes SimplexUnited States
-
National Eye Institute (NEI)UnknownKeratitis, Herpetic | Ocular Herpes Simplex
-
Wenzhou Medical UniversityUnknownCorneal Opacity | Corneal Dystrophies, Hereditary | Keratitis, Herpetic | Corneal UlcerChina
Clinical Trials on Pranoprofen
-
Università degli Studi di BresciaCompleted